QuidelOrtho Corporation· QDEL
🇺🇸 US · SmallSP600NASDAQ
- Price
- $17.58
- Day
- -0.73%
- Mkt Cap
- $1.20B
- 52W Range
- $9.92 – $35.58
- Volume
- 1.11M
- Beta
- 0.69
Find a company by name or ticker and open its page
Breaking news, press releases, and analyst updates.
Most recent articles and analysis covering this company.
Edgestream Partners L.P. purchased a new stake in QuidelOrtho Corporation (NASDAQ: QDEL) in the undefined quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor purchased 117,888 shares of the company's stock, valued at approximately $1,937,000. Edgestream Partners L.P. owned 0.17% of
Read full article
QuidelOrtho to Report Second Quarter 2026 Financial Results PR Newswire SAN DIEGO, July 24, 2026
Read full article
SAN DIEGO, July 24, 2026 /PRNewswire/ -- QuidelOrtho Corporation (Nasdaq: QDEL) (the "Company" or "QuidelOrtho"), a leading global provider of diagnostic solutions, announced today that it will report its financial results for the second quarter 2026 ended June 28, 2026, after the market closes on Thursday, August 6, 2026. Following the release of financial results, QuidelOrtho will hold a conference call beginning at 2:00 p.m.
Read full article
PHILADELPHIA--(BUSINESS WIRE)--Investor litigation firm Kaskela Law announces that it is investigating QuidelOrtho Corporation (Nasdaq: QDEL) (“QuidelOrtho”) on behalf of the company's long-term investors. Click here for additional information: https://kaskelalaw.com/case/quidelortho-corp/ Recently a securities fraud complaint was filed against QuidelOrtho on behalf of certain investors who purchased shares of the company's stock between February 17, 2022 and April 1, 2024 (the “Wrongdoing Peri.
Read full article
Investor litigation firm [url="]Kaskela Law[/url] announces that it is investigating QuidelOrtho Corporation (Nasdaq: QDEL) (âQuidelOrthoâ) on behalf of th
Read full article
SAN DIEGO, July 23, 2026 /PRNewswire/ -- QuidelOrtho Corporation (Nasdaq: QDEL), a global leader of in vitro diagnostics, has released episode 59 of its Science Bytes podcast examining how the drug overdose landscape continues to evolve and what laboratory and emergency department professionals need to know to support patient care. Based on new guidance from the Association for Diagnostics and Laboratory Medicine (ADLM), the episode explores the growing complexity of toxicology testing amid counterfeit medications, polysubstance use and emerging synthetic opioids.
Read full article
QDEL's strong portfolio, cost-saving progress and mixed first-quarter results support growth, though respiratory reliance remains a risk.
Read full article
Terumo, QuidelOrtho, Lumexa Imaging and BrainsWay are tackling industry headwinds through innovation, pricing and execution as healthcare demand stays resilient.
Read full article
SAN DIEGO, July 15, 2026 /PRNewswire/ -- QuidelOrtho Corporation (Nasdaq: QDEL)("QuidelOrtho"), a leading global provider of diagnostic solutions, today announced that the Compensation Committee of the Company's Board of Directors approved the grant of restricted stock units ("RSUs") with respect to 356,555 shares of the Company's common stock (the "Inducement Grant") to Micah Young, the Company's Chief Financial Officer and principal financial officer. The Inducement Grant was granted pursuant to the Company's 2026 Inducement Plan and as an inducement material to Mr.
Read full article